Phase 1 clinical trial of marizomib (MRZ, NPI-0052) in patients with advanced malignancies including multiple myeloma: Study NPI-0052-102 (NCT00629473) final results

Authors
Category Primary study
JournalClinical Lymphoma, Myeloma and Leukemia
Year 2015
This article has no abstract
Epistemonikos ID: 52be2548b85982fa852654cbfc6b02d3d35aec2f
First added on: Feb 07, 2025